Table 2.
Risk of cardiovascular disease in the two drug groups after propensity score matching between 2015 and 2018
| Classification | Febuxostat (27,761 patients) | Allopurinol (27,761 patients) | Crude HR (95% CI) | Adjusted HR** (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| Number of patients (n) | Person–years | Incidence rate (1000 person-years) | Number of patients (n) | Person–years | Incidence rate (1,000 person-years) | |||
| Primary outcome variable* | ||||||||
| Cardiovascular disease | 2062 | 24,369.8 | 84.6 | 2203 | 39,861.9 | 55.3 | 1.17 (1.10–1.24) | 1.11 (1.05–1.18) |
| Secondary outcome variable | ||||||||
| Myocardial infarction | 139 | 26,150.7 | 5.3 | 171 | 42,528.4 | 4.0 | 1.12 (0.90–1.41) | 1.05 (0.83–1.32) |
| Ischemic heart disease | 490 | 25,821.1 | 19.0 | 535 | 42,048.6 | 12.7 | 1.19 (1.05–1.35) | 1.11 (0.98–1.25) |
| Stroke | 656 | 25,671.7 | 25.6 | 716 | 41,756.2 | 17.1 | 1.12 (1.01–1.25) | 1.03 (0.93–1.15) |
| Transient ischemic attack | 133 | 26,155.7 | 5.1 | 164 | 42,531.1 | 3.9 | 1.12 (0.89–1.41) | 1.05 (0.83–1.33) |
| Heart failure | 939 | 25,401.6 | 37.0 | 1,033 | 41,496.4 | 24.9 | 1.16 (1.06–1.27) | 1.08 (0.99–1.18) |
| Coronary revascularization (treatment) | 59 | 26,216.6 | 2.3 | 88 | 42,632.9 | 2.1 | 1.01 (0.70–1.44) | 0.95 (0.66–1.36) |
| All-cause death | 5 | 24,369.8 | 0.2 | 9 | 39,861.9 | 0.2 | 1.02 (0.33–3.14) | 0.99 (0.32–3.07) |
*All-cause death: includes 5 and 9 patients in the febuxostat and allopurinol groups, respectively
Coronary revascularization is a treatment code that has secondary outcome variables and overlapping values
**Covariate correction: the history of cardiovascular disease before the index date
Average follow-up of 321 and 524 days in the febuxostat and allopurinol groups, respectively